The urologist's guide to low dose-rate interstitial brachytherapy with permanent seed implants for localized prostate cancer

BJU International

Volumn 99, Issue 3, 2007, Pages 497-501

  Bratt, Ola ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adverse effects; Brachytherapy; Localized; Prostate cancer; Radiotherapy; Treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; IODINE 125; NONSTEROID ANTIINFLAMMATORY AGENT; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE;

ANTIGEN DETECTION; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; DOSIMETRY; EDEMA; EXTERNAL BEAM RADIOTHERAPY; FLUOROSCOPY; HUMAN; INTERSTITIAL RADIATION; LIFE EXPECTANCY; LITHOTOMY; LOWER URINARY TRACT SYMPTOM; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROSTATITIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECURRENCE RISK; RISK FACTOR; SHORT SURVEY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME; TREATMENT PLANNING; URINE RETENTION;

BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 33846908120     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06587.x     Document Type: Short Survey

References (27)

1. Li XA, Wang JZ, Stewart RD, DiBiase SJ. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations. Phys Med Biol 2003; 48: 2753-65
2. Sacco DE, Daller M, Grocela JA, Babayan RK, Zietman AL. Corticosteroiduse after prostate brachytherapy reduces the risk of acute urinary retention. BJU Int 2003; 91: 345-9
3. Elshaikh MA, Ulchaker JC, Reddy CA et al. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebocontrolled randomized study. Int J Radiat Oncol Biol Phys 2005; 62: 164-9
4. Aus G, Abbou CC, Bolla M et al. EAU Guidelines on Prostate Cancer. Arnhem: European Association of Urology, 2006
5. Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004; 43: 316-81
6. Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol 2003; 169: 1643-52
7. Whittington R, Broderick GA, Arger P et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 44: 1107-10
8. Henderson A, Ismail AK, Cunningham M et al. Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study. Clin Oncol (R Coll Radiol) 2004; 16: 95-104
9. Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol 2002; 41: 427-33
10. Talcott JA, Clark JA, Stark PC, Mitchell SP. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 2001; 166: 494-9
11. Shah JN, Ennis RD. Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors. Int J Radiat Oncol Biol Phys 2006; 64: 817-24
12. Feigenberg SJ, Lee WR, Desilvio ML et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys 2005; 62: 956-64
13. Keyes M, Schellenberg D, Moravan V et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve? Int J Radiat Oncol Biol Phys 2006; 64: 825-34
14. Kollmeier MA, Stock RG, Cesaretti J, Stone NN. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol 2005; 173: 808-12
15. Merrick GS, Butler WM, Lief JH, Dorsey AT. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000; 47: 121-8
16. Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003; 56: 1085-92
17. Merrick GS, Butler WM, Wallner KE et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 62: 437-47
18. Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996; 14: 449-53
19. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B, Cleavinger S. Rectal function following brachytherapy with or without supplemental external beam radiation: results of two prospective randomized trials. Brachytherapy 2003; 2: 147-57
20. Beyer DC, Thomas T, Hilbe J, Swenson V. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer. Brachytherapy 2003; 2: 77-84
21. Sharkey J, Cantor A, Solc Z et al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. Brachytherapy 2005; 4: 34-44
22. Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 2006; 64: 527-33
23. Potters L, Morgenstern C, Calugaru E et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005; 173: 1562-6
24. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51: 31-40
25. Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005; 294: 1233-9
26. Ciezki JP, Reddy CA, Garcia J et al. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys 2006; 64: 512-7
27. Patel C, Elshaikh MA, Angermeier K et al. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology 2004; 63: 110-3